^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peripheral T-cell Lymphoma
    Drug:Beleodaq (belinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    01/08/2020
    Excerpt:
    Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Peripheral T-cell Lymphoma: Second-line therapy (with intention to proceed to transplant) and subsequent therapy...Preferred regimens…Belinostat